{"entity":{"id":"nct06205485","kind":"trial","name":"Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer","aka":["NEO-RT"],"tldr":"A phase 3 trial of fOLFOX (5-FU, leucovorin, oxaliplatin) and capecitabine in colorectal cancer, run by Canadian Cancer Trials Group, now recruiting.","summary":"Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer is a phase 3, randomised interventional study registered as NCT06205485 by Canadian Cancer Trials Group, with a registry enrolment figure of 250 participants, started 2024-06-26 and due to reach its primary completion in 2030-01-30. Interventions recorded: Leucovorin; Oxaliplatin; Fluoruracil; Capecitabine; Radiation. Conditions listed: Rectal Cancer. Primary outcome: Clinical response rate upon re-staging; Quality of Life defined using the LARS score. Colorectal eligibility wording from the registry: \"* Histologically confirmed invasive, well-moderately differentiated rectal adenocarcinoma, mismatch repair proficient\". Sites: Canada, United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06205485","url":"https://clinicaltrials.gov/study/NCT06205485"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","msi-high-colorectal"],"sections":[],"technologies":["cytotoxic-chemotherapy","imrt-igrt","platinum"],"targets":[],"drugs":["folfox","capecitabine"],"companies":["cctg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06205485","phase":"3","setting":"A Phase 3 Randomized Trial Of Neoadjuvant Chemotherapy, Excision And Observation Versus Chemoradiotherapy For Early Rectal Cancer","sponsor":"Canadian Cancer Trials Group","enrolled":250,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06205485/","neighbours":{"cancer":[{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"}],"company":[{"id":"cctg","kind":"company","name":"Canadian Cancer Trials Group (CCTG)","route":"/companies/cctg/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}